Magellan Diagnostics Recalls LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests Due to Risk of Falsely Low Results
CDC Health Advisory on the Recall of LeadCare® Blood Lead Tests Due to Risk of Falsely Low Results
Summary
Magellan Diagnostics, Inc. and the U.S. Food and Drug Administration (FDA) have issued a recall notice concerning the use of some LeadCare® Blood Lead Tests (certain LeadCare II, LeadCare Plus, and LeadCare Ultra test kit lots). These lots were distributed between October 27, 2020, and June 15, 2021. The use of these devices may cause serious injuries because they might underestimate blood lead levels. The FDA has identified this as a Class I recall, the most serious type of recall.
The purpose of this Centers for Disease Control and Prevention (CDC) Health Alert Network (HAN) Health Advisory is to notify healthcare providers and state and local health departments about this recall notice and to recommend appropriate follow-up actions.
Background
Magellan Diagnostics, Inc. is recalling its LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests due to a significant risk of falsely low blood lead level results. The FDA has concerns that the falsely low results may contribute to health risks in special populations such as young children and pregnant individuals. A pregnant or lactating individual’s exposure to lead is concerning because it may cause health problems for the parent and the developing baby. Obtaining falsely low blood lead level results may lead to inappropriate follow-up assessments, which may result in patient harm, including delayed puberty, reduced postnatal growth, decreased IQ, and inattention and behavior problems in children.
The FDA notified CDC on June 24 that some Magellan Diagnostics blood lead test kits were undergoing a voluntary recall by the manufacturer. The FDA is now recommending that Magellan Diagnostics customers discontinue the use of all affected test kit lots identified as part of the recall and quarantine remaining inventory.
Recommendations
- Discontinue use of all affected test kit lotsexternal icon identified as part of the recall.
- Retest children who were tested with the recalled LeadCare test kits whose results were less than 5 µg/dL, the current CDC-recommended blood lead reference value. Retesting should be done with a venous blood sample analyzed with higher complexity testing.
- Retest children who were previously tested with a LeadCare test kit if the lot number of the initial test kit is unknown and the test was done after October 27, 2020 and July 6, 2021, the date of this health advisory.
- Priority for retesting should be given to—
- Children where there is clinical concern that symptoms or developmental problems may be related to lead exposure,
- Populations at higher risk of elevated blood lead levels, such as children tested due to Medicaid-required screening or due to other state or local requirements, and
- Individuals who are pregnant or breastfeeding.
- If retesting indicates blood lead levels in excess of the current CDC Blood Level Reference Values (BLRV) or state or local action level, the healthcare provider or public health official should refer to CDC guidelines or state/local guidelines for appropriate follow-up action.
- Discuss the recall and retesting recommendations with a parent and/or caregiver of children who meet the retesting criteria.
Per CDC guidance, children with blood lead levels at or greater than 5 µg/dL should have had a subsequent test with a venous blood sample for confirmation. LeadCare instruments are currently approved for use only with capillary or finger/heel stick samples. Venous blood confirmation levels are performed with higher complexity testing such as inductively coupled plasma mass spectrometry (ICP-MS) or graphite furnace atomic absorption spectroscopy (GFAAS) and are generally considered more accurate.
More information about blood lead testing can be found by visiting—
More information about the recall can be found by visiting—
FDA Recall Notice
Magellan Diagnostics is recalling the following LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests, which were distributed from October 27, 2020 to June 15, 2021. The tests were recalled due to a significant risk of falsely low results:
- LeadCare II Blood Lead Test Kit: Lot codes 2013M, 2014M, 2015M, 2016M, 2017M, 2101M, 2103M, 2105M, 2106M, and 2107M
- LeadCare Plus Blood Lead Test Kit and LeadCare Ultra Blood Lead Test Kit: Lot codes 2011MU, 2104MU, and 2108MU
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries.
The Drugs and Medical Devices Group is responsible for ensuring medical device manufacturers and distributors comply with minimum licensing standards established to protect the health and safety of the citizens of Texas. To accomplish this objective, inspections of medical device manufacturers and distributors are conducted. If voluntary compliance with the licensing standards cannot be achieved, the Group recommends regulatory actions when necessary. In addition, the Group provides technical assistance to its licensees, answers inquiries from consumers and investigates complaints involving possible violations of the state requirements for medical device manufacturers and distributors.
Licensing
To become licensed as a medical device manufacturer or distributor, please visit the licensing requirements page, which outline options for online licensing and renewal as well as fee schedules and links to application forms.
Information on related licenses and certifications may be found by following the links below:
Email Updates
Sign up to receive email updates about important changes to the Medical Device Manufacturers and Distributors Program. This feature will serve as a tool to increase communication with license holders regarding new information added to the website.
Contact Information
For General Program Assistance
Email: Drugs and Medical Devices Group
Phone: 512-834-6755
Fax: 512-834-6759
For Licensing Assistance
Email: Drugs and Food Safety Licensing Group
Phone: 512-834-6727
Fax: 512-834-6741
Mailing addresses may be found on the contact page.